Asklepios BioPharmaceutical and Selecta Biosciences announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to MMA-101, an AAV-based gene therapy in development for the treatment of isolated methylmalonic acidemia ...